Last reviewed · How we verify
NCT00160121
Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease
Phase 4 trial testing Lanthanum carbonate in Kidney Failure, Chronic in 2,500 participants. Completed in 13 December 2005.
13 December 2005
Quick facts
| Lead sponsor | Shire |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 2,500 |
| Start date | 10 January 2005 |
| Primary completion | 13 December 2005 |
| Estimated completion | 13 December 2005 |
Drugs / interventions tested
- Lanthanum carbonate — full drug profile →
Conditions studied
- Kidney Failure, Chronic — all drugs for Kidney Failure, Chronic →
Sponsor
Shire — full company profile →
Who can join
18 and older, any sex, with Kidney Failure, Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to test how well lanthanum carbonate reduces the pre-dialysis level of serum phosphorus in subjects undergoing dialysis due to end stage renal disease and to determine the patient and physician's satisfaction.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Elemental calcium intake associated with calcium acetate/calcium carbonate in the treatment of hyperphosphatemia.
Wilson RJ, Copley JB. · · 2017 · cited 2× · PMID 28182142 · DOI 10.7573/dic.212302
Verify or expand the search:
- PubMed search for NCT00160121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lanthanum carbonate
Trials testing the same drug.
- NCT02209636 — Phosphate Lowering in CKD Trial · Phase 4 · completed
- NCT01128179 — Effects of Lanthanum Carbonate on FGF-23 in Subjects With Stage 3 CKD · Phase 2 · completed
- NCT01130831 — Effect of Lanthanum Carbonate in Patients Previously Treated With Calcium-based Phosphate Binder Therapy · completed
- NCT00452478 — Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 · Phase 4 · terminated
- NCT00557323 — Long-term Effect of Lanthanum Carbonate on Bone · completed
Other recruiting trials for Kidney Failure, Chronic
Currently open trials in the same condition.
- NCT06903559 — Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients · Phase 1, PHASE2 · recruiting
- NCT06438445 — Effects of Royal Jelly Supplementation in Chronic Kidney Disease · NA · recruiting
- NCT06288451 — DePTH: De-emphasize PTH · Phase 2 · active not recruiting
- NCT05968391 — Acetoacetate and Acetate Metabolism in Patients With Chronic Kidney Failure.(RENO-TEP) · recruiting
- NCT06314503 — First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients · NA · recruiting
Other Shire trials
Trials by the same sponsor.
- NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India · Phase 4 · recruiting
- NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism · Phase 3 · withdrawn
- NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease · Phase 3 · terminated
- NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India · completed
- NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study · Phase 4 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00160121 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shire
- Last refreshed: 2 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00160121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing